By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Investment firm RW Baird today initiated coverage of BG Medicine with an "Outperform" rating and a target price of $12 per share.

In a research note, analyst Quintin Lai wrote that the Waltham, Mass.-based developer of protein marker tests has demonstrated progress in its business, securing clearance with the US Food and Drug Administration in November for its Galectin-3 test for heart failure. Laboratory Corporation of America markets the test in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.